Polymorphs of suberoylanilide hydroxamic acid

Details Polymorphs of suberoylanilide hydroxamic acid Polymorphs of suberoylanilide hydroxamic acid

2008-03-18

2010-12-07

Sullivan, Daniel M (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C514S575000

Reexamination Certificate

active

07847122

ABSTRACT:
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6469058 (2002-10-01), Grove et al.
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: RE38506 (2004-04-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 7456219 (2008-11-01), Miller et al.
patent: 7652069 (2010-01-01), Miller et al.
patent: 2002/0183388 (2002-12-01), Gudas et al.
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammer et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0002506 (2004-01-01), Breslow et al.
patent: 2004/0018968 (2004-01-01), Sgouros et al.
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2004/0266818 (2004-12-01), Breslow et al.
patent: 2005/0004007 (2005-01-01), Grant et al.
patent: 2006/0167103 (2006-07-01), Bacopoulos et al.
patent: 2006/0276547 (2006-12-01), Bacopoulos et al.
patent: 2007/0060614 (2007-03-01), Bacopoulos et al.
patent: 2008/0119562 (2008-05-01), Richon et al.
patent: 2008/0194692 (2008-08-01), Miller et al.
patent: 2008/0227862 (2008-09-01), Richon et al.
patent: 2008/0249179 (2008-10-01), Miller et al.
patent: 2009/0012175 (2009-01-01), Bacopoulos et al.
patent: 2009/0042992 (2009-02-01), Miller et al.
patent: 2009/0054720 (2009-02-01), Sgouros et al.
patent: 0547000 (2003-06-01), None
patent: 10-262694 (1998-10-01), None
patent: WO 95/31977 (1995-11-01), None
patent: WO 97/11366 (1997-03-01), None
patent: WO 98/39965 (1998-09-01), None
patent: WO 98/40080 (1998-09-01), None
patent: WO 98/48825 (1998-11-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 99/38525 (1999-08-01), None
patent: WO 00/08048 (2000-02-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/29199 (2001-04-01), None
patent: WO 01/34199 (2001-05-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/49290 (2001-07-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/15921 (2002-02-01), None
patent: WO 02/22133 (2002-03-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/055017 (2002-07-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 03/013493 (2003-02-01), None
patent: WO 03/075839 (2003-09-01), None
DeMario et al., J. Clin. Oncol., 16:2557-2567 (1998).
Desai et al., Proc. Amer. Assoc. Cancer Res., 39:108, Abstract #736 (1998).
Desai et al., Proc. Amer. Assoc. Cancer Res., 40:362, Abstract #2396 (1999).
Leoni et al., Proc. Natl. Acad. Sci., 99:2995-3000 (2002).
Goh et al. (2001), Neoplasia, 3:331-338.
Augustine et al. (2002), Journal of the American Pharmaceutical Association, 42:93-100.
Bertolino et al. (1998), European Journal of Drug Metabolims and Pharmacokinetic, 23:223-229.
Bridgewater et al. (1998), Clinical Oncology, Review Article, 10:78-83.
Andrews et al. (2000).Intl. J. Parasitol. 30: 761-768.
Archer et al. (1998).Proc. Natl. Acad. Sci. USA95: 6791-6796.
Bhalla et al. (2002). “Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology, Abstract 4611.
Butler et al. (2000).Cancer Res. 60: 5165-5170.
Butler et al. (2001).Clincal Cancer Res. 7: 962-970.
Butler et al. (2002).Proc. Natl. Acad. Sci. USA99: 11700-11705.
Coffey et al. (2000).Medical and Pediatric Oncology35: 577-581.
Coffey et al. (2001).Cancer Res. 61: 3591-3594.
Cohen et al. (1999).Anticancer Res. 19: 4999-5006.
Cohen et al. (2002).Anticancer Res. 22: 1497-1504.
Curtin (2002).Exp. Opin. Ther. Patents12: 1375-1384.
Dressel (2000).Anticancer Res. 20: 1017-1022.
Fei et al. (2002). “Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology Abstract No. 4602.
Feinman et al. (2002). “The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology, Abstract No. 3195.
Finnin et al. (1999).Nature401: 188-193.
Furamai et al. (2001).Proc. Natl. Sci. USA98: 87-92.
Grunstein (1997).Nature389: 349-352.
He et al. (2001).J. Clin. Investigation108: 1321-1330.
Hockly et al. (2003).Proc. Natl. Acad. Sci. USA100: 2041-2046.
Kelly et al. (2001). “Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity.”American Society of Clinical Oncology, Abstract No. 344.
Kelly et al. (2002). “Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity.”American Society of Clinical Oncology, 38thAnnual Meeting of the American Society of Clinical Oncology, Nov. 7-10, 2002, Abstract No. 1831.
Kelly et al. (2002). “A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).”European J. Cancer 38(Suppl. 7): 88, Abstract No. 286.
Kim et al. (1999).Oncogene18: 2461-2470.
Kohge et al. (1998).Biochem. Pharmacol. 56: 1359-1364.
Komatsu et al. (2001).Cancer Res. 61: 4459-4466.
Kouraklis and Theocharis (2002).Curr. Med. Chem.Anti-Cancer Agents2: 477-484.
Lee et al. (2001).Cancer Res. 61: 931-934.
Lin et al. (1998).Nature391: 811-814.
Mai et al. (2001).OPPI Briefs33: 391-394.
Marks et al. (2000).J. of the Natl. Cancer Institute92: 1210-1215.
Marks et al. (2001).Clinical Cancer Res. 7: 759-760.
Marks et al. (2001).Curr. Opin. In Oncology13: 477-483.
Marks et al. (2001).Nature Reviews1: 194-202.
Miller et al. (2003).J Med Chem. 46: 5097-5116.
Munster et al. (2001).Cancer Res. 61: 8492-8497.
O'Connor et al. (2002).

Affiliated with

Also associated with

Rating

Polymorphs of suberoylanilide hydroxamic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphs of suberoylanilide hydroxamic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of suberoylanilide hydroxamic acid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4189791